Latest study: increasingly higher numbers of patients benefit from reimbursed medication


2022 07 19


In recent five years, the consumption of reimbursed medication has increased by 18 per cent or by as many as 111 daily doses per 1000 residents per day, says the analysis on the consumption of reimbursed medication, conducted by the National Health Insurance Fund (NHIF) under the Ministry of Health. According to experts, this shows a greater availability of reimbursed medication.

According to the analysis, there is a recorded annual 5 per cent increase in reimbursed medication, while the average number of doses (712) of reimbursed medication per 1000 residents, consumed last year increased by more than 7 per cent, compared to the year before (664).

‘Last year’s index of the consumption of reimbursed medication means that more than half – 57 per cent – of the daily doses, consumed in Lithuania, was covered by the Compulsory Health Insurance Fund (CHIF). In addition to that, the share of the reimbursed medication last year constituted 65 per cent of the total amount of prescription medication consumed, while the same index the year before is only 61 per cent. Thus, there is a positive tendency that an increasingly larger share of the population has their prescribed medication reimbursed. Moreover, the prospects of reaching the goal of compensating 68 per cent of the prescribed medication by 2027, established in the Medication Policy Guidelines, are becoming quite realistic.’ says Evaldas Stropus, Head of the Pharmaceuticals Reimbursement Division at the NHIF.

A NHIF study has also shown that the majority of medication (nearly 63 per cent), consumed in Lithuania last year was for the improvement of cardiovascular system. Approximately 10 per cent of the medication used was for gastrointestinal tract and metabolism, while approx. 7 per cent – for nervous system. Similar tendencies were recorded in previous years.

‘Last year 1000 residents shared 445 daily doses of reimbursed medication for cardiovascular system. The share of the reimbursed medication that belongs to this category, constitutes as much as 85 per cent, compared to other groups medication.’ says Stropus.

The NHIF analysis has also shown that the number of average daily doses of consumed reimbursed generic and biosimilar medication has slightly increased, constituting 63 per cent of the total reimbursed medication consumed, compared to 2020. According to calculations, the consumption of generic and biosimilar medication has increased by approximately 45 per cent in five years.

During the study it was noted that the majority of the CHIF funds is spent to reimburse original medication, although the number of prescriptions for this medication, compared to generic and reference medication, is the lowest. In 2021, the average price of generic medication prescription was approx. 15.25 Eur, reference medication – 19.71 Eur, and original – 192.88 Eur.

According to calculations, CHIF costs for original medication last year increased by approx. 1.3 per cent. Experts say that this could be influenced by the introduction of reimbursement of new and expensive medication, an increased consumption of expensive original medication, reimbursed earlier, and extended indications for the prescription of certain medication.

The entire report on consumption of reimbursed medication in 2021 is available here.

(Piktochart pict.)

The NHIF invites you:

Your questions are welcome by email [email protected] or phone: local (8 5) 232 2222, international +370 5 232 222